Bioequivalence Endpoints Successfully Met for Humira Biosimilar, Coherus Announces
Targeted Regenerative Meds Hold Promise for RA Patients Resistant to anti-TNF Agents
Diabetes Drugs Could Be Next Frontier of Biosimilar Development
Will the Biosimilars Bubble Burst Even Before It Expands?
New Mexico Senate Passes Bill for Biosimilar Substitution
FDA Should Forge Ahead on Biosimilar Drug Reviews: A Rheumatologist's Opinion
Amgen-Harvard Pilgrim Enter Outcomes-Based Contract for Enbrel
Truxima Receives Approval in EU for Autoimmune, Oncology Indications
Will US Follow UK on Managed Biosimilar Switching of IBD Patients on Infliximab?
Biosimilars Council Wants Elimination of 6-Month Exclusivity for Biologics
How Will the Genentech-Amgen Feud Bear Down on Biosimilar Development?
FDA Accepts Mylan-Biocon Pegfilgrastim Biosimilar Application
AbbVie, Novartis Unhappy With FDA Guidance on Naming Biologics and Biosimilars
Herceptin, Rituxan Biosimilars Might Soon Reach Oncologists in Europe
Efficacy and Safety of Anti-TNF-alpha Biosimilars Comparable to Reference Drugs in RA and AS
Bevacizumab Biosimilar Could Address Global Barriers to Access
Does a Drug's Mechanism Regulate Retention by Patients With Psoriasis?
New Player in the Biosimilars Game: Aurobindo Pharma
Legal and Regulatory Decisions Likely to Drive Biosimilar Approvals in 2017
Will 2017 Change the Fate of Biosimilars? An Update From the CBI Summit
Biosimilar Knowledge Gaps Identified Among US Specialty Physicians
How Will Pfizer's Infliximab Biosimilar Compete With Remicade?
ECCO Supports Switching From Remicade to Biosimilar Infliximab for IBD Patients
EMA Pilot Will Provide Tailored Advice to Biosimilar Developers, Similar to FDA Process
Treating Rheumatoid Arthritis With Biologic Medications: A Quick Take
The FDA vs the EC: Two Very Different Ways to Address Biosimilar Education
EMA Concerns Prompt Sandoz to Withdraw Neulasta Biosimilar Application
What Influences Physicians' Decisions About Patient Suitability for Biosimilar Infliximab?
Three Insulin Makers Face Class-Action Lawsuit on Price Fixing
FDA Filing of Sandoz's Humira Biosimilar Delayed